Literature DB >> 24211447

Eukaryotic translation initiation is controlled by cooperativity effects within ternary complexes of 4E-BP1, eIF4E, and the mRNA 5' cap.

Anna Modrak-Wojcik1, Michal Gorka, Katarzyna Niedzwiecka, Konrad Zdanowski, Joanna Zuberek, Anna Niedzwiecka, Ryszard Stolarski.   

Abstract

Initiation is the rate-limiting step during mRNA 5' cap-dependent translation, and thus a target of a strict control in the eukaryotic cell. It is shown here by analytical ultracentrifugation and fluorescence spectroscopy that the affinity of the human translation inhibitor, eIF4E-binding protein (4E-BP1), to the translation initiation factor 4E is significantly higher when eIF4E is bound to the cap. The 4E-BP1 binding stabilizes the active eIF4E conformation and, on the other hand, can facilitate dissociation of eIF4E from the cap. These findings reveal the particular allosteric effects forming a thermodynamic cycle for the cooperative regulation of the translation initiation inhibition.
© 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  4E binding protein 1; 4E-BP1; 7-methylguanosine 5′-triphosphate; Analytical ultracentrifugation; DB; Fluorescence; SPR; TCEP; TFA; Translation initiation; dialysis buffer; eIF4E; eukaryotic initiation factor 4E; m(7)GTP; mRNA 5′cap; surface plasmon resonance; trifluoroacetic acid; tris (2-carboxyethyl) phosphine HCl

Mesh:

Substances:

Year:  2013        PMID: 24211447     DOI: 10.1016/j.febslet.2013.10.043

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

1.  Modified ARCA analogs providing enhanced translational properties of capped mRNAs.

Authors:  Ilona Kocmik; Karolina Piecyk; Magdalena Rudzinska; Anna Niedzwiecka; Edward Darzynkiewicz; Renata Grzela; Marzena Jankowska-Anyszka
Journal:  Cell Cycle       Date:  2018-08-17       Impact factor: 4.534

Review 2.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 3.  CRISPR-derived genome editing therapies: Progress from bench to bedside.

Authors:  Holly A Rees; Alex C Minella; Cameron A Burnett; Alexis C Komor; Nicole M Gaudelli
Journal:  Mol Ther       Date:  2021-10-05       Impact factor: 11.454

4.  Akt-mTOR hypoactivity in bipolar disorder gives rise to cognitive impairments associated with altered neuronal structure and function.

Authors:  Amanda M Vanderplow; Andrew L Eagle; Bailey A Kermath; Kathryn J Bjornson; Alfred J Robison; Michael E Cahill
Journal:  Neuron       Date:  2021-03-24       Impact factor: 17.173

5.  Distinct features of cap binding by eIF4E1b proteins.

Authors:  Dorota Kubacka; Ricardo Núñez Miguel; Nicola Minshall; Edward Darzynkiewicz; Nancy Standart; Joanna Zuberek
Journal:  J Mol Biol       Date:  2014-11-15       Impact factor: 5.469

6.  BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.

Authors:  Pei Wan; Zhilin Chen; Weifeng Zhong; Huiming Jiang; Zhicheng Huang; Dong Peng; Qiang He; Nanhui Chen
Journal:  Oncol Rep       Date:  2020-10-08       Impact factor: 3.906

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.